North American Morning Briefing : Futures Rise on -2-

Published on 06/04/2025 at 06:22

Dow Jones

Cencora, Inc.

-1.16%

Cardinal Health, Inc.

-1.02%

Blueprint Medicines Corporation

+0.14%

Oshkosh Corporation

+1.00%

Advance Auto Parts, Inc.

-1.94%

Kymera Therapeutics, Inc.

+1.85%

Pinterest, Inc.

0.00%

VersaBank

+1.21%

VersaBank (VBNK.T) is expected to report $0.27 for 2Q.

ANALYST RATINGS ACTIONS

Advance Auto Parts Raised to Neutral From Sell by Redburn Atlantic

Block Raised to Outperform From In-Line by Evercore ISI Group

Blueprint Medicines Cut to Equal-Weight From Overweight by Stephens & Co.

Blueprint Medicines Cut to Market Perform From Market Outperform by JMP Securities

Blueprint Medicines Cut to Peer Perform From Outperform by Wolfe Research

Bumble Cut to Underweight From Neutral by JP Morgan

Cardinal Health Raised to Overweight From Equal-Weight by Wells Fargo

Cencora Raised to Overweight From Equal-Weight by Wells Fargo

Kymera Therapeutics Raised to Buy From Neutral by B. Riley Securities

Kymera Therapeutics Raised to Overweight From Equal-Weight by Morgan Stanley

Metals Acquisition Cut to Market Perform From Outperform by BMO Capital

Oshkosh Raised to Buy From Hold by Truist Securities

Pinterest Raised to Overweight From Neutral by JP Morgan

This article is a text version of a Wall Street Journal newsletter published earlier today.

(END) Dow Jones Newswires

06-04-25 0621ET

Latest news about Blueprint Medicines Corporation

Blueprint Medicines Corporation Announces Termination of Financing Agreement	07:50am	CI
Blueprint Medicines Corporation Announces Directorate and Committee Changes	07:50am	CI
Sanofi completed the acquisition of Blueprint Medicines Corporation from Sixth Street Partners, LLC.	06:50am	CI
Sanofi Closes Acquisition of Blueprint Medicines	06:28am	MT
Sanofi completes acquisition of Blueprint Medicines	02:04am	RE
Sanofi Closes Blueprint Medicines Purchase Following Tender Offer	01:26am	MT
Sanofi Closes Blueprint Medicines Purchase	01:10am	MT
Sanofi Extends Tender Offer for US-based Blueprint Medicines	Jul. 17	MT
Sanofi announces extension of Blueprint tender offer	Jul. 17	RE
Blueprint Medicines Corporation(NasdaqGS:BPMC) dropped from S&P TMI Index	Jul. 16	CI
Blueprint Medicines Corporation(NasdaqGS:BPMC) dropped from S&P Global BMI Index	Jul. 16	CI
Blueprint Medicines Corporation(NasdaqGS:BPMC) dropped from S&P Biotechnology Select Industry Index	Jul. 16	CI
Blueprint Medicines Corporation(NasdaqGS:BPMC) dropped from NASDAQ Biotechnology Index	Jul. 15	CI
Wells Fargo Downgrades Blueprint Medicines to Equalweight From Overweight, Price Target is $129	Jun. 17	MT
Blueprint Medicines Corporation Announces Data Reinforcing Sustained Clinical Efficacy and Well-Tolerated Safety Profile of Long-Term AYVAKIT® (avapritinib) Treatment at 2025 EHA and EAACI Congresses	Jun. 12	CI
Blueprint Medicines Announces Data Reinforcing Safety Profile Of Long-Term Ayvakit	Jun. 12	RE
The Week’s Biggest Mergers Unpacked	Jun. 06
Blueprint Medicines Insider Sold Shares Worth $340,033, According to a Recent SEC Filing	Jun. 05	MT
UBS Adjusts Price Target on Blueprint Medicines to $129 From $88, Maintains Neutral Rating	Jun. 05	MT
Citigroup Upgrades Blueprint Medicines to Neutral From Sell, $129 Price Target	Jun. 04	MT
North American Morning Briefing : Futures Rise on -2-	Jun. 04	DJ
Guggenheim Downgrades Blueprint Medicines to Neutral From Buy, Price Target is $132	Jun. 03	MT
Wolfe Downgrades Blueprint Medicines to Peer Perform From Outperform	Jun. 03	MT
Stephens Downgrades Blueprint Medicines to Equalweight From Overweight, Adjusts PT to $135 From $150	Jun. 03	MT
TD Cowen Downgrades Blueprint Medicines to Hold From Buy, Price Target is $130	Jun. 03	MT